NCT02213328View on ClinicalTrials.gov

Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents

PHASE2CompletedINTERVENTIONAL
Enrollment

148

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

March 6, 2017

Study Completion Date

March 6, 2017

Conditions
HIV Infections
Interventions
DRUG

Truvada

Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.

Trial Locations (2)

1862

Perinatal HIV Non-network Research CRS, Soweto

Unknown

Desmond Tutu HIV Foundation Non-Network CRS, Cape Town

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT02213328 - Acceptability, Safety, and Use of Daily Truvada Pre-Exposure Prophylaxis in Adolescents | Biotech Hunter | Biotech Hunter